Plain-English translation of NCT07400835 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research is testing whether DNA methylation markers—a type of genetic fingerprint—found in urine and vaginal samples can help doctors identify which women with postmenopausal bleeding are at risk for endometrial cancer. Right now, doctors rely on ultrasound and invasive biopsies to check for this cancer, which creates anxiety and unnecessary procedures for most women (since only 5–10% actually have cancer). The study hopes to develop a simpler, non-invasive test that women can do themselves.
Endometrial cancer is one of the most common cancers in women, and early detection saves lives. However, the current diagnostic process—using ultrasound and biopsies—is often inaccurate, causing many healthy women to undergo unnecessary invasive procedures. This trial aims to create a safer, easier, patient-friendly test to identify who really needs further evaluation.
You likely qualify if…
You likely don't qualify if…
You would provide urine and vaginal samples that you collect yourself, plus allow a clinician to collect a cervical sample during your routine gynecology visit. These samples will be tested for DNA methylation markers to see if they can predict cancer risk. The study is recruiting 600 women and is being conducted in Denmark.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Denmark